| No. |
Proposition |
|
For |
Against |
Abstain |
| 1 |
Approval of the parent company financial statements for the year ended 31 December2025 |
|
|
|
|
| 2 |
Approval of the consolidated financial statements for the year ended 31 December2025 |
|
|
|
|
| 3 |
Appropriation of 2025 earnings and setting of dividend |
|
|
|
|
| 4 |
Approval of the regulated agreements specified in Articles L.225-38 etseq of the Commercial Code |
|
|
|
|
| 5 |
Approval of the remuneration policy for directors |
|
|
|
|
| 6 |
Approval of the remuneration policy for the Chairman of the Board of Directors |
|
|
|
|
| 7 |
Approval of the remuneration policy for the Chief Executive Officer and Deputy Chief Executive Officers |
|
|
|
|
| 8 |
Approval of the information about the remuneration of corporate officers mentioned in paragraphI of Article L.22-10-9 of the Commercial Code |
|
|
|
|
| 9 |
Approval of the components of the total remuneration and benefits of all kinds paid during or awarded in respect of the 2025 financial year to MartinBouygues, Chairman of the Board of Directors |
|
|
|
|
| 10 |
Approval of the components of the total remuneration and benefits of all kinds paid during or awarded in respect of the 2025 financial year to Olivier Roussat, Chief Executive Officer |
|
|
|
|
| 11 |
Approval of the components of the total remuneration and benefits of all kinds paid during or awarded in respect of the 2025 financial year to Pascal Grang, Deputy Chief Executive Officer |
|
|
|
|
| 12 |
Approval of the components of the total remuneration and benefits of all kinds paid during or awarded in respect of the 2025 financial year to Edward Bouygues, Deputy Chief Executive Officer |
|
|
|
|
| 13 |
Renewal of the term of office of Benot Maes as a director |
|
|
|
|
| 14 |
Renewal of the term of office of Alexandre de Rothschild as a director |
|
|
|
|
| 15 |
Authorisation to the Board of Directors to trade in the company’s shares, for a period of eighteen months |
|
|
|
|
| 16 |
Authorisation to the Board of Directors, for a period of eighteen months, to reduce the share capital by cancelling shares held by the company |
|
|
|
|
| 17 |
Delegation of competence to the Board of Directors, for a period of twenty-six months, to increase the share capital, without pre-emptive rights for existing shareholders, for the benefit of employees or corporate officers of the company or related companies who are members of a company savings scheme |
|
|
|
|
| 18 |
Authorisation to the Board of Directors, for a period of twenty-six months, to allot existing or new shares free of charge, entailing the waiver by shareholders of their pre-emptive rights, in favour of employees or corporate officers of the company or related companies |
|
|
|
|
| 19 |
Authorisation to the Board of Directors, for a period of twenty-six months, to allot existing or new shares free of charge as a retirement benefit, entailing the waiver by shareholders of their pre-emptive rights, in favour of eligible employees or corporate officers of the company or related companies |
|
|
|
|
| 20 |
Delegation of competence to the Board of Directors, for a period of eighteen months, to issue equity warrants during the period of a public offer for the company’s shares, up to a limit of 25% of the share capital |
|
|
|
|
| 21 |
Powers to accomplish formalities |
|
|
|
|